WAYNESBORO, Tenn. — Wayne Medical Center (WMC) recently added Genius™ 3D Mammography™ developed by Hologic, Inc., to its range of imaging services, according to CEO Tyler Taylor.
Genius 3D exams use advanced breast imaging technology and are clinically proven to significantly increase the detection of breast cancers, while decreasing the number of women asked to return for additional testing.
“We are pleased to enhance the availability of advanced imaging technology at Wayne Medical Center through the addition of this state-of-the-art mammography system,” said Taylor. “This technology provides our technologists and radiologists with enhanced capability to identify breast cancer while reducing additional testing.”
A Genius exam uses breast tomosynthesis technology to create a three-dimensional image of the breast structure, which enables radiologists to see with greater clarity through overlapping tissue to detect cancers, often at an earlier stage.
A Genius exam includes both 2D and 3D images. During the 3D portion of the exam, an X-ray arm sweeps in a slight arc over the breast, taking multiple images. A computer then converts the images into a stack of thin layers, allowing the radiologist to review the breast tissue one layer at a time. A Genius exam requires no additional compression and takes only a few seconds longer than a conventional 2D breast cancer screening exam.
A Genius 3D Mammography exam is clinically proven to be a better option for women of all breast densities compared to 2D alone. Researchers have found that:
- The Genius 3D Mammography exam finds 20-65% more invasive breast cancers compared to 2D alone, an average increase of 41%.3
- Only the Genius 3D Mammography exam is FDA-approved as superior for women with dense breasts compared to 2D alone.1-2
- The Genius 3D Mammography exam reduces callbacks by up to 40% compared to 2D alone.2,4
Most insurance will cover a 3D exam; however, WMC offers patients their choice of either a conventional 2D mammogram or the Genius 3D exam. To schedule a mammogram at Wayne Medical Center, call 931.380.4044.
References:
1) FDA submissions P080003, P080003/S001, P080003/S004, P080003/S005
2) Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507.
3) Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499 2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions ® on screening outcomes. Individual results may vary. The study found an average 41% (95% CI: 20-65%) increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
4) Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
5) Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis(3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
6) McDonald ES, Oustimov A, Weinstein SP, et al. Effectiveness of Digital Breast Tomosynthesis Compared With Digital Mammography: Outcomes Analysis From 3 Years of Breast Cancer Screening. JAMA Oncol. 2016 Jun 1;2(6):737-43.
7) Rafferty EA, Durand MA, Conant EF, et al Breast Cancer Screening Using Tomosynthesis and Digital Mammography in Dense and Nondense Breasts.
JAMA. 2016 Apr 26;315(16):1784-6.